Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACCELERATE: Risk-adapted Chemoimmunotherapy for Relapsed/Refractory ALK+ ALCL
NCT07013565Phase 2Recruiting
- Sponsor
- New York Medical College
- Start
- Aug 2025
- Primary completion
- Jul 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in Anaplastic Large Cell Lymphoma ALK-positive, sponsored by New York Medical College. Started Aug 2025; status: recruiting.
02
Drugs
03
Conditions
Anaplastic Large Cell Lymphoma ALK-positive
Beyond the preview
Go deeper on NCT07013565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07013565.